Women and heart disease

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Women's Health

Background:

• Coronary heart disease (CHD) and vascular diseases cause about half of all female deaths.
• Despite similar pathophysiology (atherosclerosis, thrombosis) to men, clinical endpoints are delayed in women.
• Endogenous estrogens are hypothesized to delay vascular disease onset, with CHD rare in premenopausal women and increasing post-menopause.

Purpose of the Study:

• To explore the potential of estrogen-replacement therapy (ERT) for primary prevention of cardiovascular disease (CVD) in postmenopausal women.
• To review the known cardioprotective mechanisms of estrogens.
• To assess the effectiveness of secondary preventative measures in women compared to men.

Main Methods:

• Review of existing literature on estrogen's effects on CVD.
• Analysis of observational studies supporting ERT for primary prevention.
• Comparison of ERT benefits with standard secondary prevention therapies.

Main Results:

• Estrogens offer cardioprotective benefits, including improved plasma lipids, anti-platelet effects, preserved endothelium-mediated vasodilation, and antioxidant properties.
• Observational studies suggest ERT may retard CVD development.
• Standard secondary preventative measures (aspirin, beta-blockade, ACE inhibitors, statins) appear equally effective in women and men.

Conclusions:

• Estrogen replacement therapy is a potential strategy for primary cardiovascular disease prevention in postmenopausal women.
• While observational data is supportive, definitive results from prospective randomized controlled trials are pending.
• Physicians may underutilize evidence-based secondary prevention interventions in high-risk women.